Johnson & Johnson

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About JNJ

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. 

CEO
Joaquin Duato
CEOJoaquin Duato
Employees
140,800
Employees140,800
Headquarters
New Brunswick, New Jersey
HeadquartersNew Brunswick, New Jersey
Founded
1887
Founded1887
Employees
140,800
Employees140,800

JNJ Key Statistics

Market cap
586.64B
Market cap586.64B
Price-Earnings ratio
22.07
Price-Earnings ratio22.07
Dividend yield
2.11%
Dividend yield2.11%
Average volume
9.11M
Average volume9.11M
High today
$245.35
High today$245.35
Low today
$242.61
Low today$242.61
Open price
$243.96
Open price$243.96
Volume
13.27M
Volume13.27M
52 Week high
$246.35
52 Week high$246.35
52 Week low
$141.50
52 Week low$141.50

Stock Snapshot

As of today, Johnson & Johnson(JNJ) shares are valued at $244.72. The company's market cap stands at 586.64B, with a P/E ratio of 22.07 and a dividend yield of 2.1%.

On 2026-02-16, Johnson & Johnson(JNJ) stock traded between a low of $242.61 and a high of $245.35. Shares are currently priced at $244.72, which is +0.9% above the low and -0.3% below the high.

Johnson & Johnson(JNJ) shares are trading with a volume of 13.27M, against a daily average of 9.11M.

During the past year, Johnson & Johnson(JNJ) stock moved between $141.50 at its lowest and $246.35 at its peak.

During the past year, Johnson & Johnson(JNJ) stock moved between $141.50 at its lowest and $246.35 at its peak.

JNJ News

Simply Wall St 44m
Should J&J’s Talc Verdict and Mounting Lawsuits Prompt Reassessment From Johnson & Johnson Investors?

In February 2026, a Philadelphia jury found Johnson & Johnson liable for its talc-based baby powder contributing to a woman’s ovarian cancer death, awarding US$...

Should J&J’s Talc Verdict and Mounting Lawsuits Prompt Reassessment From Johnson & Johnson Investors?
Simply Wall St 1d
Assessing Johnson & Johnson Valuation After Fresh Talc Litigation Verdict And Ongoing Legal Risks

Johnson & Johnson (JNJ) is back in the legal spotlight after a Pennsylvania jury found the company responsible for talc baby powder contributing to a woman’s ov...

Assessing Johnson & Johnson Valuation After Fresh Talc Litigation Verdict And Ongoing Legal Risks
Benzinga 2d
Jury: Johnson & Johnson Liabile in Case Linking Baby Powder to Cancer

On Friday, a Pennsylvania state-court jury in Philadelphia ordered Johnson & Johnson (NYSE:JNJ) to pay $250,000 to the family of Gayle Emerson, finding the comp...

Jury: Johnson & Johnson Liabile in Case Linking Baby Powder to Cancer

Analyst ratings

57%

of 28 ratings
Buy
57.1%
Hold
35.7%
Sell
7.1%

More JNJ News

Simply Wall St 3d
Protagonist Therapeutics Milestones Test Valuation As NDAs And Trials Advance

Protagonist Therapeutics submitted NDAs for Icotrokinra in plaque psoriasis and Rusfertide in polycythemia vera, advancing two late stage drug candidates. The...

Protagonist Therapeutics Milestones Test Valuation As NDAs And Trials Advance
Simply Wall St 4d
Johnson And Johnson News Links Clotting Breakthrough To MedTech Trial Progress

Scientists have identified a genetic cause linked to rare blood clotting events associated with Johnson & Johnson's COVID vaccine. Johnson & Johnson reported e...

Johnson And Johnson News Links Clotting Breakthrough To MedTech Trial Progress
24/7 Wall St. 4d
Pentair Just Paid Out: Is This Industrial Dividend Built to Last?

Pentair Just Paid Out: Is This Industrial Dividend Built to Last? Quick Read Pentair (PNR) delivered its 50th consecutive annual dividend increase. The 8.0% ra...

Pentair Just Paid Out: Is This Industrial Dividend Built to Last?
Nasdaq 6d
Is Johnson & Johnson a Buy, Sell, or Hold in 2026?

Key Points Johnson & Johnson has crushed the market over the past year. The healthcare giant faces some challenges that could harm its results. However, John...

Is Johnson & Johnson a Buy, Sell, or Hold in 2026?

People also own

Based on the portfolios of people who own JNJ. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.